Gilead Sciences, Inc. Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $30.5B+5.9% YoYTTM through 30 Jun 2026
Net Income -$3.2B-775.0% YoYTTM through 30 Jun 2026
Free Cash Flow $12.9BTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| Gross Margin | 78.4% |
| EBITDA Margin | 0.2% |
| Operating Margin | 34.0% |
| Net Margin | -10.6% |
Returns
37.5%ROE
14.4%ROA
Balance Sheet Health
Debt / Equity1.10x
Current Ratio1.97x
Net Debt$14.3B
Cash & Equivalents$3.2B
Quality Metrics
Altman Z-Score3.61
Piotroski F-Score4 / 9
FCF Margin42.5%
Rule of 4043.3
Earnings-Beat Rate100.0%
Multi-Year Trend
RevenueFY2025: $29.4B
Diluted EPS-$2.65TTMFY2025: $6.78
Dividend
$1.64Per share, FY20262.29%Yield-10.4%5-yr growth
Capital Allocation
Capex Intensity2.0%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| HIV | $20.8B | +6.0% | View detailsGilead expects continued growth in product sales, particularly in the HIV segment, driven by Biktarvy and the launch of Yeztugo. |
| Liver Disease | $3.2B | +6.0% | View detailsExpected to build on the launch of Livdelzi for liver disease. |
| Veklury | $911M | -49.0% | View detailsAnticipated decreases in Veklury sales in 2026. |
| Oncology (Trodelvy) | $1.4B | +6.0% | View detailsGilead plans to maintain focus on pipeline advancement in oncology. |
| Cell Therapy | $1.8B | -7.0% | View detailsAnticipated decreases in Cell Therapy sales in 2026. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.